How eConsent Expands Patient Access, Reduces Costs And Improves Time To Treatment

A precision medicine company focused on the development of new therapies for age-related macular degeneration required a deeper understanding of the disease. However, the study design proved to be too expensive and difficult to execute using a traditional trial approach.

Existing study methods required 100+ physical sites, and were limited by patient proximity to those sites, which resulted in the study being delayed for years.

By deploying Medable eConsent, eRecruitment and Direct-to-Patient shipments, the study was able to take place for the first time ever.